Chembio Diagnostics (CEMI) Appoints Leslie Teso-Lichtman to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
May 24, 2022 4:15 PM EDTHAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembios 2022 Annual Meeting of Stockholders.
We are excited to have Leslie join the Chembio Board of Directors, said Richard Eberly, Chembios Chief Executive Officer and President. Her significant experience in corporate financial leadership at global diagnostics companies will be an important asset as we strive to create value through our Global Competitiveness program by leveraging Chembios broad product portfolio and operations worldwide.
Ms.... More
